Personnel changes in many pharmaceutical companies! Involving the chairman, vice president, deputy general manager...

Every month, a group of senior executives in the pharmaceutical industry leave their jobs, and the changes in personnel are often only superficial phenomena, behind which are more drastic changes and reshaping of the market structure

01 15 executives resigned

"Golden Nine Silver Ten", entering September, the senior management of the pharmaceutical industry still changes frequently

Chairman of the board

Stellite

On September 16, Stellite issued an announcement stating that Chairman Hu Jinsheng had resigned as chairman due to his age

It is worth noting that Hu Jinsheng will continue to serve as a director and a member of the strategy committee of the board of directors

According to the 2021 semi-annual report, Stellite achieved revenue of 855 million yuan, an increase of 18.

As the leading domestic iodine contrast agent raw material medicine, Stellite also reached a cooperation agreement with Hengrui, the leading domestic iodine contrast agent preparation

In the fifth round of national procurement, 2 specifications for Shanghai Stellite Iohexol injection and 1 product specification for Iodixanol injection won the bid

There is no doubt that this will be a good opportunity for Stellite to expand its market share

Hanhui Pharmaceutical

From September 1st, Hanhui Pharmaceuticals has replaced Liu Qi as the chairman of Hanhui Pharmaceuticals by Chen Xiaohua, and Li Yue has replaced Hu Zhiqiang as the CEO of Hanhui Pharmaceuticals.

According to the WeChat public account "Pharmaceutical Representative", in May of this year, Hanhui Pharmaceutical had adjusted its organizational structure and no longer established a national sales department and COO position

vice president

Fosun Pharma

On September 23, Fosun Pharma issued an announcement stating that senior executive Lihui Zou had applied for resignation due to personal reasons and would no longer serve as the vice president from September 22, 2021

In the 2021 semi-annual report, Fosun Pharma’s pharmaceutical business achieved revenue of 12.

Fosun Pharma said that the growth in performance was mainly due to the increased volume of new products.

In June of this year, Fosun Kate’s Akirensai injection was launched.

BeiGene

On September 16, according to the WeChat public account "Medicine Representative", Wu Qingyi, Senior Vice President of BeiGene and Chief Commercial Officer of Greater China, will leave the company.

On September 17, BeiGene's value exceeded 336.

BeiGene's high investment has also been rewarded accordingly
.

On the evening of August 25, BeiGene announced its latest early stage R&D pipeline layout and development progress at the Global R&D Day investor conference call
.
It is reported that Baekje currently has more than 50 preclinical projects, of which about half have Fist-in-class potential, and more than 10 projects will enter the clinical stage in the next 24 months
.

Ogilvy Medical

On September 6, Ogilvy Medical issued an announcement stating that Vice President and Chief Financial Officer Huang Wenjian had applied for the resignation of the company's director, vice president and chief financial officer due to personal reasons
.
After resignation, Huang Wenjian will not work in the company
.

Deputy General Manager

Gan Li Pharmaceutical

On September 11, Gan Li Pharmaceutical issued an announcement stating that the deputy general manager Lawrence Allan Hill had applied for the resignation of the deputy general manager due to personal reasons
.

On September 30, the resignation application took effect
.

The 2021 semi-annual report shows that Ganli Pharmaceutical's revenue in the first half of the year was approximately 1.
475 billion yuan, an increase of 22.
2% year-on-year; the net profit attributable to shareholders of listed companies was approximately 373 million yuan, an increase of 21.
17% year-on-year
.

In the sixth round of centralized drug procurement (insulin special) organized by the state, many products of Ganli Pharmaceutical ranked among them.
As the third-generation insulin leading company in China, Ganli Pharmaceutical's market share successfully exceeded 10% in 2020
.

Lanzhou Forci Pharmaceutical

On September 3, Lanzhou Forci Pharmaceutical Co.
, Ltd.
issued an announcement stating that Lv Zhiying, deputy general manager and chief financial officer, applied to resign from the positions of deputy general manager and chief financial officer due to job transfer.
After resignation, he would no longer hold any positions in the company or its subsidiaries
.

02 The market promotes transformation

From the above combing point of view, vice presidents and deputy general managers are easily changed positions in domestic pharmaceutical companies
.
Although most of the reasons for resignation are "personal reasons", it is undeniable that resignation is also related to the tremendous pressure faced by the pharmaceutical industry
.

Under the influence of the new crown epidemic, many pharmaceutical companies have to seek new marketing models
.
Coupled with the consistency evaluation, the normalization of national procurement is advancing, and pharmaceutical companies must face transformation and upgrading
.

Not only resignations occur from time to time, but the frequency of actions such as mergers and acquisitions, reorganizations, and "weight reduction" among pharmaceutical companies is also very high.
The adjustment of personnel and strategy is only a superficial phenomenon, and behind it is more drastic changes and reshaping of the market structure
.

Taking Hengrui Medicine as an example, after the change of coaches, many big moves were launched
.

September 5, announced a cooperation agreement with Beijing-day Biotechnology Co.
, Ltd.
Guangzhou real
.
Tianguangshi Biologics granted Hengrui Pharmaceutical the exclusive and exclusive commercialization rights for the third-generation anti-CD20 monoclonal antibody MIL62 in the Greater China region.
At the same time, it cooperated with Hengrui Pharmaceutical to develop the clinical development of the combination of MIL62 and the company's products
.

Hengrui intends to make an equity investment of approximately US$30 million in Tianguangshi Biology as a cornerstone investor
.

On August 26, Hengrui Medicine also announced the signing of a strategic cooperation agreement with Dalian Wanchun Bulin Pharmaceutical Co.
, Ltd.
, a subsidiary of Wanchun Medicine
.

According to data from the interim report, Hengrui's innovative drugs achieved sales revenue of 5.
207 billion yuan, a year-on-year increase of 43.
80%, accounting for 39.
15% of overall sales revenue
.
This proportion is obviously not enough
.

Under the changing times, Hengrui, which used to cover its head and focused on R&D, began to "buy, buy and buy" to increase the proportion of sales of innovative drugs through cooperation, so as to better cope with the impact of the decline in the sales of generic drugs
.

Based on the announcements and public news of many pharmaceutical companies, it is not fully disclosed where the executives have gone after leaving
.
However, the demand for talents in the pharmaceutical industry has never been reduced.
This also requires pharmaceutical professionals to quickly integrate into the transformation trend of relevant pharmaceutical companies in order to be ready for competition at all times
.